Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

RA Capital Management

Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:

Top 5 stock holdings are ASND, Parabilis Medicines, RYTM, PCVX, SION, and represent 46.73% of Ra Capital Management's stock portfolio.
Added to shares of these 10 stocks: ASND (+$2.7B), Parabilis Medicines (+$792M), Hemab Therapeutics Holdings (+$287M), ABVX (+$151M), ORKA (+$148M), ARTV (+$79M), NTLA (+$77M), DFTX (+$71M), SANA (+$65M), PRLD (+$35M).
Started 17 new stock positions in AURA, Jatt Ii Acquisition Corp, FTH, NTLA, QTTB, Hemab Therapeutics Holdings, Seaport Therapeutics, Parabilis Medicines, DFTX, ALT. SANA, Amanat Acquisition Corp, ABVX, ASND, EDIT, ORKA, PRLD.
Reduced shares in these 10 stocks: Ascendis Pharma A S (-$2.4B), DNTH (-$219M), NUVL (-$159M), PRAX (-$120M), SRPT (-$85M), EWTX (-$83M), SYRE (-$82M), VOR (-$55M), FULC (-$46M), OLMA (-$39M).
Sold out of its positions in SYRE, Ascendis Pharma A S, RNA, CTNM, DSGN, DNTH, FULC, GRAL, HNGE, INSP. MPLT, OLMA, PRAX, RLMD, SRPT, WGS, STRO, TVTX.
Ra Capital Management was a net buyer of stock by $1.2B.
Ra Capital Management has $12B in assets under management (AUM), dropping by 21.93%.
Central Index Key (CIK): 0001346824

Tip: Access up to 7 years of quarterly data

Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Ra Capital Management

Ra Capital Management holds 84 positions in its portfolio as reported in the June 2026 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Ascendis Pharma A/s Common Stock (ASND)	23.8	$2.7B	NEW	10M	266.72	View chart
Parabilis Medicines Common Stock	6.9	$792M	NEW	29M	27.37	View chart
Rhythm Pharmaceuticals Common Stock (RYTM)	6.4	$740M		6.7M	111.03	View chart
Vaxcyte Common Stock (PCVX)	5.8	$667M		12M	58.13	View chart
Sionna Therapeutics Common Stock (SION)	3.8	$436M		9.9M	43.99	View chart
Tyra Biosciences Common Stock (TYRA)	3.4	$390M		12M	31.94	View chart
Edgewise Therapeutics Common Stock (EWTX)	3.0	$341M	-19%	8.4M	40.63	View chart
Newamsterdam Pharma Co Nv Common Stock (NAMS)	2.8	$324M		9.6M	33.89	View chart
Hemab Therapeutics Holdings Common Stock	2.5	$287M	NEW	7.8M	36.73	View chart
Septerna Common Stock (SEPN)	2.0	$234M		7.0M	33.49	View chart
Bicara Therapeutics Common Stock (BCAX)	1.9	$215M		7.3M	29.69	View chart
Mineralys Therapeutics Common Stock (MLYS)	1.8	$208M		7.7M	26.98	View chart
Gh Research Common Stock (GHRS)	1.8	$205M		7.6M	26.88	View chart
Disc Medicine Common Stock (IRON)	1.6	$179M		2.5M	73.14	View chart
Spyglass Pharma Common Stock (SGP)	1.6	$179M		8.0M	22.26	View chart
Artiva Biotherapeutics Common Stock (ARTV)	1.5	$174M	+82%	18M	9.70	View chart
Janux Therapeutics Common Stock (JANX)	1.5	$172M		11M	15.36	View chart
Taysha Gene Therapies Common Stock (TSHA)	1.4	$160M		24M	6.81	View chart
Biocryst Pharmaceuticals Common Stock (BCRX)	1.4	$158M		16M	10.00	View chart
Wave Life Sciences Common Stock (WVE)	1.4	$157M		27M	5.81	View chart
Nuvalent Inc-a Common Stock (NUVL)	1.3	$154M	-50%	1.2M	123.50	View chart
Abivax Sa- Adr (ABVX)	1.3	$151M	NEW	1.1M	133.26	View chart
Oruka Therapeutics Common Stock (ORKA)	1.3	$148M	NEW	1.6M	95.17	View chart
Climb Bio Common Stock (CLYM)	1.3	$147M		11M	13.04	View chart
Solid Biosciences Common Stock (SLDB)	1.0	$120M	+28%	12M	9.99	View chart
Zai Lab Ltd- Adr (ZLAB)	0.9	$109M		5.7M	19.00	View chart
Ars Pharmaceuticals Common Stock (SPRY)	0.8	$87M		11M	8.01	View chart
Xencor Common Stock (XNCR)	0.7	$85M	+7%	5.3M	16.10	View chart
Jade Biosciences Common Stock (JBIO)	0.7	$82M		3.7M	22.22	View chart
Intellia Therapeutics Common Stock (NTLA)	0.7	$77M	NEW	4.5M	16.92	View chart
Lb Pharmaceuticals Common Stock (LBRX)	0.6	$72M		2.2M	32.45	View chart
Definium Therapeutics Common Stock (DFTX)	0.6	$71M	NEW	1.5M	47.04	View chart
Aclaris Therapeutics Common Stock (ACRS)	0.6	$67M	+86%	13M	5.29	View chart
4d Molecular Therapeutics In Common Stock (FDMT)	0.6	$67M		5.0M	13.30	View chart
Sana Biotechnology Common Stock (SANA)	0.6	$65M	NEW	19M	3.49	View chart
Damora Therapeutics Common Stock (DMRA)	0.5	$62M		2.4M	26.01	View chart
Monopar Therapeutics Common Stock (MNPR)	0.5	$62M		667k	92.59	View chart
Acumen Pharmaceuticals Common Stock (ABOS)	0.5	$56M		21M	2.67	View chart
Geron Corp Common Stock (GERN)	0.5	$55M	-32%	43M	1.28	View chart
Rezolute Common Stock (RZLT)	0.4	$49M	+2%	9.4M	5.20	View chart
Evommune Common Stock (EVMN)	0.4	$46M		3.5M	13.29	View chart
Vor Biopharma Common Stock (VOR)	0.4	$44M	-55%	2.4M	18.41	View chart
Century Therapeutics Common Stock (IPSC)	0.4	$44M		18M	2.45	View chart
Aktis Oncology Common Stock (AKTS)	0.4	$42M	-12%	1.3M	32.23	View chart
Bioage Labs Common Stock (BIOA)	0.4	$41M		1.7M	24.51	View chart
C4 Therapeutics Common Stock (CCCC)	0.3	$37M		8.0M	4.67	View chart
Mirum Pharmaceuticals Common Stock (MIRM)	0.3	$37M		319k	117.07	View chart
Capricor Therapeutics Common Stock (CAPR)	0.3	$36M		1.5M	24.08	View chart
Pepgen Common Stock (PEPG)	0.3	$36M		20M	1.80	View chart
Prelude Therapeutics Common Stock (PRLD)	0.3	$35M	NEW	6.5M	5.33	View chart
Nkarta Common Stock (NKTX)	0.3	$31M		11M	2.83	View chart
Q32 Bio Common Stock (QTTB)	0.3	$30M	NEW	2.3M	12.74	View chart
Anteris Technologies Global Common Stock (AVR)	0.3	$30M		3.0M	9.85	View chart
Editas Medicine Common Stock (EDIT)	0.3	$29M	NEW	8.9M	3.24	View chart
Ovid Therapeutics Common Stock (OVID)	0.2	$28M		11M	2.69	View chart
Assembly Biosciences Common Stock (ASMB)	0.2	$28M		1.0M	27.48	View chart
Alx Oncology Holdings Common Stock (ALXO)	0.2	$27M		13M	2.07	View chart
Benitec Biopharma Common Stock (BNTC)	0.2	$25M		1.9M	13.38	View chart
Lenz Therapeutics Common Stock (LENZ)	0.2	$24M		4.2M	5.68	View chart
Lexeo Therapeutics Common Stock (LXEO)	0.2	$23M		5.0M	4.66	View chart
Acrivon Therapeutics Common Stock (ACRV)	0.2	$22M	+46%	12M	1.78	View chart
Altimmune Common Stock (ALT)	0.2	$20M	NEW	6.5M	3.04	View chart
Karyopharm Therapeutics Common Stock (KPTI)	0.2	$19M		1.9M	9.77	View chart
Bright Minds Biosciences Common Stock (DRUG)	0.2	$19M		265k	70.20	View chart
Avalo Therapeutics Common Stock (AVTX)	0.2	$19M	+50%	1.0M	18.48	View chart
Onkure Therapeutics Inc-a Common Stock (OKUR)	0.2	$18M		4.0M	4.56	View chart
Faeth Therapeutics Common Stock (FTH)	0.2	$18M	NEW	722k	25.00	View chart
Aura Biosciences Common Stock (AURA)	0.2	$18M	NEW	2.5M	7.10	View chart
Sab Biotherapeutics Common Stock (SABS)	0.1	$17M		4.4M	3.90	View chart
Seaport Therapeutics Common Stock	0.1	$15M	NEW	700k	21.72	View chart
Palisade Bio Common Stock (PALI)	0.1	$15M		7.1M	2.09	View chart
Helix Acquisition Corp-cl A Common Stock (HLXC)	0.1	$13M		1.3M	10.64	View chart
Waystar Holding Corp Common Stock (WAY)	0.1	$11M		529k	20.53	View chart
Equillium Common Stock (EQ)	0.1	$9.9M		3.1M	3.20	View chart
Macrogenics Common Stock (MGNX)	0.1	$8.6M		1.9M	4.62	View chart
Perceptive Capital Solutions Common Stock (PCSC)	0.1	$8.2M		750k	10.88	View chart
Adicet Bio Common Stock (ACET)	0.1	$8.1M	-21%	933k	8.64	View chart
Newamsterdam Pharma Co Nv-27 WTS (NAMSW)	0.1	$7.1M		333k	21.37	View chart
Corvus Pharmaceuticals Common Stock (CRVS)	0.1	$6.7M		450k	14.94	View chart
Rani Therapeutics Holdings-a Common Stock (RANI)	0.1	$6.5M		8.5M	0.76	View chart
Jatt Ii Acquisition Corp Common Stock	0.0	$5.7M	NEW	500k	11.36	View chart
Amanat Acquisition Corp Cl A Common Stock	0.0	$3.8M	NEW	375k	10.16	View chart
Werewolf Therapeutics Common Stock (HOWL)	0.0	$859k	-64%	2.4M	0.36	View chart
Palatin Technologies Common Stock (PTN)	0.0	$670k	-11%	62k	10.79	View chart

Past Filings by Ra Capital Management

SEC 13F filings are viewable for Ra Capital Management going back to 2010

Ra Capital Management 2026 Q2 filed Aug. 14, 2026
Ra Capital Management 2026 Q1 filed May 15, 2026
Ra Capital Management 2025 Q4 filed Feb. 17, 2026
Ra Capital Management 2025 Q3 filed Nov. 14, 2025
Ra Capital Management 2025 Q2 filed Aug. 14, 2025
Ra Capital Management 2025 Q1 filed May 15, 2025
Ra Capital Management 2024 Q4 filed Feb. 14, 2025
Ra Capital Management 2024 Q3 filed Nov. 14, 2024
Ra Capital Management 2024 Q2 filed Aug. 14, 2024
Ra Capital Management 2024 Q1 amended filed May 17, 2024
Ra Capital Management 2024 Q1 filed May 15, 2024
Ra Capital Management 2023 Q4 filed Feb. 14, 2024
Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
Ra Capital Management 2023 Q3 filed Nov. 14, 2023
Ra Capital Management 2023 Q2 filed Aug. 14, 2023
Ra Capital Management 2023 Q1 filed May 15, 2023

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z